Bio-Techne Corp. | Balance Sheet

Fiscal year is July-June. All values USD Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
363
111
96
158
182
Total Accounts Receivable
55
70
93
117
120
Inventories
39
50
57
60
86
Other Current Assets
12
18
8
13
11
Total Current Assets
469
248
254
348
398
Net Property, Plant & Equipment
117
130
132
135
145
Total Investments and Advances
14
-
-
40
3
Intangible Assets
260
683
741
1,031
1,044
Other Assets
2
2
2
4
3
Total Assets
862
1,063
1,130
1,558
1,593
ST Debt & Current Portion LT Debt
-
4
4
-
-
Accounts Payable
10
13
21
17
18
Income Tax Payable
-
2
2
2
9
Other Current Liabilities
16
20
28
116
52
Total Current Liabilities
26
40
54
136
80
Long-Term Debt
-
73
92
344
339
Provision for Risks & Charges
-
39
39
-
-
Deferred Taxes
34
61
63
121
86
Other Liabilities
7
3
3
9
9
Total Liabilities
67
216
250
609
514
Common Equity (Total)
795
847
879
950
1,079
Total Shareholders' Equity
795
847
879
950
1,079
Total Equity
795
847
879
950
1,079
Liabilities & Shareholders' Equity
862
1,063
1,130
1,558
1,593

About Bio-Techne

View Profile
Address
614 McKinley Place NE
Minneapolis Minnesota 55413
United States
Employees -
Website http://www.bio-techne.com
Updated 07/08/2019
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community.